Search

Find what you’re looking for

34 results 'Bohus' in All Content

Looking for product information? 

Get information about products, solutions for your application and how to contact our experts.

Product search

Nouryon to double capacity of Kromasil® chromatography media in Sweden to meet growing demand for peptide-based diabetes and obesity treatments

Nouryon today announced the expansion of its Kromasil® chromatography media manufacturing facility in Bohus, Sweden. Construction will begin in early 2025, and the start of production is expected in early 2027. This expansion will double the facility’s capacity to meet the growing global demand for peptide-based drugs in the GLP-1 receptor agonist class. Kromasil® chromatography media, a key product in the Company's Consumer & Life Sciences segment, plays a crucial role for purifying novel peptide-based pharmaceuticals, including treatments for type 2 diabetes and obesity.

https://www.nouryon.com/news-and-events/news-overview/2025/nouryon-to-double-capacity-of-kromasil-chromatography-media-in-sweden-to-meet-growing-demand-for-peptide-based-diabetes-and-obesity-treatments/

Nouryon to expand its Kromasil® facility to meet global pharma and biotech demand

Plan to invest in its Kromasil® manufacturing facility in Bohus, Sweden, to meet the increasing global demand from the pharmaceutical and biotechnology industries for high-performing solutions. The investment is expected to double the facility’s existing production capacity, which will strengthen Nouryon’s global leadership position in high-performance silica.

https://www.nouryon.com/news-and-events/news-overview/2021/expanding-kromasil-facility-to-meet-global-pharma--and-biotech-demand/

We respect your privacy.

We use essential and non-essential cookies to provide, secure, analyze and improve our services. Click 'Agree' to accept or learn more about our Cookie Policy and edit your preferences. 

You can change settings at any time.

Edit